Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). J of Skin. 2017;1(3.1):s128. doi:10.25251/skin.1.supp.127